Antisense Therapeutics Limited
ATHJFOTCHealthcare
$0.01
$-0.04(-76.00%)
Market Cap$19635001
P/E Ratio—
52W High$0.075
52W Low$0.01
Antisense Therapeutics Limited (ATHJF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATHJF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-06 | 2023-06 | 2022-06 | 2021-06 | 2020-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.97M | $1.58M | $1.78M | $0.58M | $0.67M |
| Cost of Revenue | $0.06M | $0.10M | $0.09M | $0.10M | $0.11M |
| Gross Profit | $2.91M | $1.48M | $1.69M | $0.47M | $0.56M |
| Gross Margin %(computed) | 97.91% | 93.97% | 94.98% | 82.12% | 83.90% |
| Operating Expenses | |||||
| R&D Expenses | $10.70M | $10.16M | $4.54M | $4.91M | $1.90M |
| G&A Expenses | $0.55M | $3.05M | $2.92M | $3.56M | $4.46M |
| Total Operating Expenses | $14.74M | $13.34M | $7.61M | $8.68M | $6.67M |
| Operating Income | ($11.83M) | ($13.34M) | ($7.61M) | ($8.68M) | ($6.67M) |
| Operating Margin %(computed) | -398.65% | -844.70% | -428.10% | — | -997.30% |
| Interest Income | $0.62M | $0.38M | $0.03M | $0.00M | $0.03M |
| Interest Expense | $0.00M | $0.01M | $0.01M | $0.01M | $0.01M |
| Income Before Tax | ($11.92M) | ($11.38M) | ($5.81M) | ($8.06M) | ($5.91M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($11.92M) | ($11.38M) | ($5.81M) | ($8.06M) | ($5.91M) |
| Net Margin %(computed) | -401.57% | -720.31% | -326.89% | — | -883.89% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 |
| Wtd Avg Shares | 881.21M | 668.85M | 631.79M | 540.98M | 454.51M |
| EBITDA | ($11.90M) | ($11.37M) | ($5.83M) | ($8.10M) | ($5.99M) |
| EBITDA Margin %(computed) | -400.93% | -719.53% | -327.74% | — | -896.72% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Antisense Therapeutics Limited data
About Antisense Therapeutics Limited (ATHJF) Income Statement
Antisense Therapeutics Limited (ATHJF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ATHJF reported revenue of $0.00B, gross profit of $0.00B (gross margin 97.91%), and net income of ($0.01B) — a net profit margin of -401.57%.
Frequently asked questions
ATHJF · 4 questionsAntisense Therapeutics Limited (ATHJF) reported revenue of $0.00B for 2024, up 87.9% year-over-year.
ATHJF revenueATHJF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09